Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics Limited, formerly known as PharmAust Limited, reported a significant increase in other income and a substantial rise in losses for the half-year ended 31 December 2024. The company experienced an increase in net assets, yet its loss from ordinary activities and overall loss rose dramatically, indicating challenging financial circumstances. The acquisition of Neurizon Therapeutics LLC highlights a shift in control within the company.
More about Pharmaust Limited
YTD Price Performance: -23.08%
Average Trading Volume: 5,882
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €38.74M
See more data about NUZ stock on TipRanks’ Stock Analysis page.